Legislative Breakthrough for Alzheimer’s Research and Treatment
New Laws to Drive Progress in Understanding and Treating Alzheimer’s
The National Alzheimer’s Project Act (NAPA) Reauthorization Act and the Alzheimer’s Accountability and Investment Act were signed into law by President Biden, a major milestone in the fight against Alzheimer’s disease.
The NAPA Act reauthorizes the National Alzheimer’s Project Act through 2035, providing a roadmap for federal efforts in responding to Alzheimer’s and other dementias. The Alzheimer’s Accountability and Investment Act ensures scientists can directly communicate with Congress about the resources they need to effectively treat the disease.
Pivotal Moment in the Fight Against Alzheimer’s
"This action marks a major step in tackling Alzheimer’s and delivering a needed dose of hope to those living with this devastating disease and their loved ones," said Congressman Paul Tonko (NY-20). "The enactment of the NAPA Reauthorization Act and Alzheimer’s Accountability and Investment Act will equip us with the tools and resources necessary to address Alzheimer’s and ease the heavy burden on patients and their families."
Support from the Alzheimer’s Association
The Alzheimer’s Association celebrated the signing of the new laws, emphasizing the importance of the measures in advancing research, detection, risk reduction, raising awareness, and enhancing caregiver support. "We are grateful to the President and lawmakers in the House and Senate for working together in a bipartisan manner to address this growing public health crisis," said a statement from the organization.
New York State Impacted
In New York State, an estimated 410,000 people have Alzheimer’s disease or a related disorder, making it essential for continued support and research.
Conclusion
The signing of the NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act represents a significant step forward in the fight against Alzheimer’s. With these new laws, scientists, patients, and caregivers can rely on a roadmap for federal efforts and the resources necessary to address this devastating disease.
Frequently Asked Questions
Q: What is the National Alzheimer’s Project Act (NAPA)?
A: NAPA is a federal law that provides a roadmap for responding to Alzheimer’s and other dementias.
Q: What does the Alzheimer’s Accountability and Investment Act do?
A: This act ensures scientists can directly communicate with Congress about the resources they need to effectively treat Alzheimer’s.
Q: Why is this important?
A: These new laws will drive progress in understanding and treating Alzheimer’s, providing hope to patients and their families.
Q: How many people are affected by Alzheimer’s in New York State?
A: An estimated 410,000 people in New York State have Alzheimer’s disease or a related disorder.
Q: What are the implications of these new laws?
A: The laws will provide a roadmap for federal efforts, resources, and support for scientists, patients, and caregivers, driving progress in understanding and treating Alzheimer’s.
